Relmada Therapeutics/$RLMD
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Relmada Therapeutics
Relmada Therapeutics Inc is a clinical-stage, publicly traded biotechnology company focused on the development of NDV-01 and sepranolone. NDV-01 is a novel, controlled-release intravesical formulation of gemcitabine and docetaxel. NDV-01 is currently in a Phase 2 clinical trial in Isreal to assess its safety and efficacy in patients with aggressive forms of non-muscle invasive bladder cancer (NMIBC). Sepranolone is a novel neurosteroid epimer of allopregnanolone. sepranolone is being developed for the potential treatment of Prader-Willi Syndrome, Tourette Syndrome, excessive tremor and other diseases related to excessive GABAergic activity.
Ticker
$RLMD
Sector
Primary listing
Employees
17
Headquarters
Website
RLMD Metrics
BasicAdvanced
$674M
-
-$1.45
0.73
-
Price and volume
Market cap
$674M
Beta
0.73
52-week high
$7.51
52-week low
$0.24
Average daily volume
2.5M
Financial strength
Current ratio
14.615
Quick ratio
14.463
Profitability
Management effectiveness
Return on assets (TTM)
-50.24%
Return on equity (TTM)
-94.05%
Valuation
Price to book
5.45
Price to tangible book (TTM)
5.45
Price to free cash flow (TTM)
-5.544
Free cash flow yield (TTM)
-18.04%
Free cash flow per share (TTM)
-1.16
Growth
Earnings per share change (TTM)
-45.18%
3-year earnings per share growth (CAGR)
-35.03%
What the Analysts think about RLMD
Analyst ratings (Buy, Hold, Sell) for Relmada Therapeutics stock.
RLMD Financial Performance
Revenues and expenses
RLMD Earnings Performance
Company profitability
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Relmada Therapeutics stock?
Relmada Therapeutics (RLMD) has a market cap of $674M as of March 28, 2026.
What is the P/E ratio for Relmada Therapeutics stock?
The price to earnings (P/E) ratio for Relmada Therapeutics (RLMD) stock is 0 as of March 28, 2026.
Does Relmada Therapeutics stock pay dividends?
No, Relmada Therapeutics (RLMD) stock does not pay dividends to its shareholders as of March 28, 2026.
When is the next Relmada Therapeutics dividend payment date?
Relmada Therapeutics (RLMD) stock does not pay dividends to its shareholders.
What is the beta indicator for Relmada Therapeutics?
Relmada Therapeutics (RLMD) has a beta rating of 0.73. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.